GetTopicDetailResponse(id=029212e5849e, topicName=龍膽苦苷, introduction=, content=帕金森病 龍膽苦苷, image=null, comments=1, allHits=289, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Thu Jun 05 15:04:11 CST 2025, time=2025-06-05, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=505260, tagList=[TagDto(tagId=505260, tagName=龍膽苦苷)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2268165, encodeId=c7dc2268165de, content=<a href='/topic/show?id=029212e5849e' target=_blank style='color:#2F92EE;'>#龍膽苦苷#</a>（Gentiopicroside，GPS），是從龍膽科植物（如<a href='/topic/show?id=c5d01060e9d8' target=_blank style='color:#2F92EE;'>#龍膽草#</a>、<a href='/topic/show?id=550510534e53' target=_blank style='color:#2F92EE;'>#秦艽#</a>等）中提取的一種<a href='/topic/show?id=950612e59277' target=_blank style='color:#2F92EE;'>#環(huán)烯醚萜苷類#</a>化合物。靶向<a href='/topic/show?id=eb20105009e6' target=_blank style='color:#2F92EE;'>#膽汁酸受體#</a>TGR5激活<a href='/topic/show?id=7ee51303e38' target=_blank style='color:#2F92EE;'>#Nrf2#</a><a href='/topic/show?id=6b1b553e2a6' target=_blank style='color:#2F92EE;'>#抗氧化#</a>信號(hào)通路，從而減輕<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>癥狀的潛力。
實(shí)際上抗氧化能力的<a href='/topic/show?id=5c1d22423c8' target=_blank style='color:#2F92EE;'>#中藥#</a>以及西藥都是很多的，但是不同的抗氧化通路可能有一定的差異。象這項(xiàng)研究中認(rèn)為Nrf2這個(gè)通路，并不具備特異性，更不具備對(duì)帕金森病的特異性。未來(lái)還要深入研究。象秦艽這類中藥，整體還是安全的，對(duì)中中樞神經(jīng)系統(tǒng)疾病有一定的調(diào)控作用，值得深入研究。龍膽苦苷的更多作用機(jī)制值得深入。
, objectTitle=重大突破！中草藥再立功！龍膽苦苷靶向 TGR5 激活Nrf2抗氧化信號(hào)減輕帕金森病, objectType=article, longId=880659, objectId=07ee880659fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241106/1730860333483_8538692.jpg, objectUrl=/article/show_article.do?id=07ee880659fc, replyNumber=0, likeNumber=37, createdTime=2025-06-06, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=07ee880659fc, moduleTitle=重大突破！中草藥再立功！龍膽苦苷靶向 TGR5 激活Nrf2抗氧化信號(hào)減輕帕金森病, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=07ee880659fc)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2268073, encodeId=78fb22680e349, content=<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a> <a href='/topic/show?id=029212e5849e' target=_blank style='color:#2F92EE;'>#龍膽苦苷#</a>, objectTitle=重大突破！中草藥再立功！龍膽苦苷靶向 TGR5 激活Nrf2抗氧化信號(hào)減輕帕金森病, objectType=article, longId=880659, objectId=07ee880659fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241106/1730860333483_8538692.jpg, objectUrl=/article/show_article.do?id=07ee880659fc, replyNumber=0, likeNumber=37, createdTime=2025-06-05, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=07ee880659fc, moduleTitle=重大突破！中草藥再立功！龍膽苦苷靶向 TGR5 激活Nrf2抗氧化信號(hào)減輕帕金森病, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=07ee880659fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-06-05發(fā)表于上海
